Key insights
- The FDA warns of a potential shortage of neurosurgery supplies lasting until 2026 due to a recall by Medline Industries. This may negatively impact hospital margins and patient care, but the overall effect on the broader US equity market is expected to be minimal.
Investing.com -- The U.S. Food and Drug Administration on Wednesday said supply disruptions of sterile pads, sponges and strips used in neurosurgery could continue through the end of 2026.
The agency added neurosurgical patties, sponges and strips to its medical device shortages list. The products are used during neurosurgery and microsurgery to absorb fluid and protect delicate tissue.
In March, manufacturer Medline Industries recalled neurosurgical patties in its neuro sponge line due to elevated endotoxin levels, with no return date set, according to the FDA.
Use of affected products could lead to health problems requiring medical or surgical treatment, including fever, inflammation, low blood pressure or nausea, the FDA said.
The agency said it is working with other manufacturers and healthcare providers to monitor supplies and evaluate ways to reduce the impact on patients.
The FDA has instructed healthcare providers to conserve the products whenever possible and reserve them for the most critical cases, including brain surgery and procedures where alternatives are not suitable.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.